How should I manage an 83-year-old woman with Alzheimer’s disease, depression, and hypercholesterolemia who is on escitalopram 20 mg daily and multiple daytime and nighttime doses of trazodone, and who is now restless, has had two days of insomnia followed by excessive daytime sleep, misses meals, frequently refuses medications, and is receiving hospice care?

Discontinue Trazodone and Simplify the Medication Regimen

The current trazodone regimen (175 mg total daily in multiple doses) is inappropriate and likely contributing to this patient's erratic sleep-wake cycle and should be discontinued. The American Academy of Sleep Medicine explicitly recommends against using trazodone for insomnia treatment 1, and this excessive dosing pattern—with daytime administration—is worsening her circadian disruption rather than helping it.

Why the Current Approach is Failing

This patient is receiving trazodone 175 mg/day split across multiple doses including morning and afternoon administration. This is pharmacologically counterproductive:

• Trazodone causes significant daytime sedation 2, which explains why she sleeps excessively during the day after missing sleep
• The multiple daytime doses are directly causing the sedation that leads to missed meals
• This creates a vicious cycle: daytime sedation → nighttime wakefulness → more daytime sedation
• In hospice patients with dementia, medication refusal is common 3, and forcing multiple daily doses of a sedating medication is impractical

Immediate Management Steps

1. Discontinue All Trazodone

• Taper over 1-2 weeks to avoid withdrawal symptoms (irritability, anxiety, sleep disruption) 4
• The 2017 AASM guideline specifically states clinicians should NOT use trazodone for sleep disturbances 1
• Even in palliative care settings where trazodone is sometimes listed as an option, the recommended dose is 25-100 mg at bedtime only—not multiple daytime doses 3

2. Address Medication Refusal and Hospice Goals

Since she frequently refuses medications and is on hospice:

• Reassess goals of care with the hospice team—is treating restlessness improving her quality of life or causing more distress?
• Consider whether the escitalopram 20 mg is still indicated. In hospice patients with weeks-to-days life expectancy, antidepressants may be discontinued 3
• Benzodiazepines should be avoided in elderly patients with dementia due to cognitive impairment, falls risk, and paradoxical agitation 5, 6, 7

3. For Refractory Nighttime Restlessness (If Treatment Desired)

If the patient and family want pharmacologic management after trazodone discontinuation:

First-line option for hospice patients with dementia:

• Quetiapine 2.5-5 mg PO at bedtime 3
  • Lower fall risk than benzodiazepines
  • Addresses both agitation and sleep
  • Can be given as a single evening dose
  • Start at 2.5 mg given medication refusal patterns

Alternative if quetiapine ineffective:

• Olanzapine 2.5 mg PO at bedtime 3
• Chlorpromazine 25-50 mg PO/PR at bedtime for dying patients 3

Avoid:

• Zolpidem (high fall risk, next-morning impairment in elderly) 3, 8
• Lorazepam (cognitive impairment, falls, paradoxical agitation in dementia) 5, 6, 7
• Any benzodiazepine receptor agonist in this population 5

Non-Pharmacologic Interventions

These are critical in hospice dementia patients and may be more acceptable than medications:

• Sleep hygiene: Consistent wake time, minimize daytime napping, bright light exposure during waking hours 1, 5
• Treat contributing factors: Pain assessment (she may be restless due to uncontrolled pain), constipation, urinary retention 3
• Environmental modifications: Quiet room at night, comfortable temperature, familiar objects 5
• Structured daily routine: Regular meal times, activities during the day to maintain circadian rhythm 5

Critical Caveats

1. The escitalopram may not be helping: Recent evidence suggests SSRIs have minimal benefit for agitation in Alzheimer's disease and may increase fall risk 9. Consider discussing deprescribing with hospice team 6, 7.

2. Polypharmacy in hospice dementia: This patient exemplifies inappropriate polypharmacy. The 2025 frailty-dementia guidelines emphasize deprescribing anticholinergics, benzodiazepines, and unnecessary medications 6.

3. Medication refusal is a symptom: Rather than forcing medications, explore whether her refusal indicates discomfort with the regimen or a desire for less intervention—both appropriate in hospice care.

4. Hypercholesterolemia treatment: If she's on a statin, this should likely be discontinued in hospice as it provides no short-term benefit and adds to pill burden 7.

Bottom Line

Stop the trazodone entirely, simplify to single-dose evening medication if any pharmacotherapy is used, and prioritize comfort measures over aggressive symptom control. The current regimen is iatrogenic—the medications are causing the problem they're meant to solve. In a hospice patient with advanced dementia who refuses medications, less is definitively more 3, 6.